The Johns Hopkins University spinout’s latest funding will go toward further developing its lead candidate, VTA-110, for muscular dystrophy treatments.

WuXi AppTec and New World Development-backed Adagene has raised close to $140m in its initial public offering after having secured $155m in equity financing.

The Telefónica-backed digital mental health services provider has secured an extension to close its series A round at $36m.

Optum has co-led a $26 round for the health network provider, whose existing shareholders include iCarbonX.

Ascletis Pharma has returned for an $80m round that will fund the further clinical development of a potential treatment for non-alcoholic steatohepatitis symptoms.

The $9.5m investment vehicle will be run by Opt unit Bonds Investment Group for up to 13 years, targeting local entrepreneurs.

Caltech spinout Talis Biomedical has raised more than $220m in an initial public offering on the Nasdaq Global Market.

Equip has raised $17m in total to make eating disorder treatment accessible.

Based in Shanghai, China, Zou has worked her way up from investment manager since joining LAV in May 2015.

Ensoma has emerged with $70m in series A financing to advance research from Fred Hutchinson and University of Washington.